Related papers: Probabilistic Clustering using Shared Latent Varia…
Alzheimer's disease (AD) is a degenerative brain disease impairing a person's ability to perform day to day activities. The clinical manifestations of Alzheimer's disease are characterized by heterogeneity in age, disease span, progression…
Alzheimer's Disease (AD) research has shifted to focus on biomarker trajectories and their potential use in understanding the underlying AD-related pathological process. A conceptual framework was proposed in modern AD research that…
Predicting the risk of clinical progression from cognitively normal (CN) status to mild cognitive impairment (MCI) or Alzheimer's disease (AD) is critical for early intervention in Alzheimer's disease (AD). Traditional survival models often…
In this work, we consider the problem of predicting the course of a progressive disease, such as cancer or Alzheimer's. Progressive diseases often start with mild symptoms that might precede a diagnosis, and each patient follows their own…
Alzheimers Disease (AD) is a progressive neurodegenerative disorder that poses significant challenges in its early diagnosis, often leading to delayed treatment and poorer outcomes for patients. Traditional diagnostic methods, typically…
Several biomarkers are hypothesized to indicate early stages of Alzheimer's disease, well before the cognitive symptoms manifest. Their precise relations to the disease progression, however, is poorly understood. This lack of understanding…
Background. Alzheimer's disease and related dementia (ADRD) are characterized by multiple and progressive anatomo clinical changes. Yet, modeling changes over disease course from cohort data is challenging as the usual timescales are…
Progressive cognitive decline spanning across decades is characteristic of Alzheimer's disease (AD). Various predictive models have been designed to realize its early onset and study the long-term trajectories of cognitive test scores…
Pre-symptomatic (or Preclinical) Alzheimer's Disease is defined by biomarker evidence of fibrillar amyloid beta pathology in the absence of clinical symptoms. Clinical trials in this early phase of disease are challenging due to the slow…
Early diagnosis of Alzheimer's disease is a challenge because the existing methodologies do not identify the patients in their preclinical stage, which can last up to a decade prior to the onset of clinical symptoms. Several research…
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects cognitive functions such as memory, thinking, and behavior. In this disease, there is a critical phase, mild cognitive impairment, that is really…
Multiple types or views of data (e.g. genetics, proteomics) measured on the same set of individuals are now popularly generated in many biomedical studies. A particular interest might be the detection of sample subgroups (e.g. subtypes of…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, structural brain changes, and genetic predispositions. This study leverages machine-learning and statistical techniques to investigate…
A novel framework is proposed for handling the complex task of modelling and analysis of longitudinal, multivariate, heterogeneous clinical data. This method uses temporal abstraction to convert the data into a more appropriate form for…
Alzheimer's Disease (AD) is a complex neurodegenerative disorder marked by memory loss, executive dysfunction, and personality changes. Early diagnosis is challenging due to subtle symptoms and varied presentations, often leading to…
Alzheimer's Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the pathophysiology of which is very complex and largely unknown. Event-based modeling (EBM) is a data-driven technique to estimate the sequence in…
Neurodegeneration as measured through magnetic resonance imaging (MRI) is recognized as a potential biomarker for diagnosing Alzheimer's disease (AD), but is generally considered less specific than amyloid or tau based biomarkers. Due to a…
Alzheimer's disease (AD) is characterized by complex and largely unknown progression dynamics affecting the brain's morphology. Although the disease evolution spans decades, to date we cannot rely on long-term data to model the pathological…
Recent studies on modelling the progression of Alzheimer's disease use a single modality for their predictions while ignoring the time dimension. However, the nature of patient data is heterogeneous and time dependent which requires models…
Alzheimer's disease (AD) is the most common neurodegenerative disease in older people. Despite considerable efforts to find a cure for AD, there is a 99.6% failure rate of clinical trials for AD drugs, likely because AD patients cannot…